Ultragenyx Pharmaceutical (NASDAQ:RARE) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a report issued on Wednesday, BidAskClub reports.

Other research analysts have also recently issued research reports about the stock. Wedbush reaffirmed a “buy” rating and issued a $75.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Thursday, August 15th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, September 4th. ValuEngine cut shares of Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Thursday, September 5th. Cowen reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Thursday, August 15th. Finally, Morgan Stanley decreased their target price on shares of Ultragenyx Pharmaceutical from $83.00 to $79.00 and set an “overweight” rating on the stock in a research report on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $74.23.

NASDAQ RARE traded up $0.23 during trading hours on Wednesday, reaching $44.92. The company had a trading volume of 19,674 shares, compared to its average volume of 519,554. The stock has a 50-day moving average of $55.85 and a 200 day moving average of $61.69. Ultragenyx Pharmaceutical has a 1-year low of $37.44 and a 1-year high of $90.98. The company has a current ratio of 9.32, a quick ratio of 9.14 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $2.59 billion, a P/E ratio of -6.09 and a beta of 2.13.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.72) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.73) by $0.01. Ultragenyx Pharmaceutical had a negative net margin of 527.49% and a negative return on equity of 49.84%. The company had revenue of $24.15 million for the quarter, compared to analysts’ expectations of $22.16 million. During the same quarter in the prior year, the company posted ($1.06) earnings per share. Ultragenyx Pharmaceutical’s revenue for the quarter was up 88.8% compared to the same quarter last year. As a group, sell-side analysts predict that Ultragenyx Pharmaceutical will post -7.03 EPS for the current year.

In related news, EVP Karah Herdman Parschauer sold 1,489 shares of the company’s stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $63.01, for a total transaction of $93,821.89. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Emil D. Kakkis bought 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 11th. The shares were purchased at an average price of $43.63 per share, for a total transaction of $218,150.00. Following the completion of the purchase, the chief executive officer now directly owns 472,479 shares of the company’s stock, valued at approximately $20,614,258.77. The disclosure for this purchase can be found here. 7.80% of the stock is currently owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP increased its stake in Ultragenyx Pharmaceutical by 120.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 136,555 shares of the biopharmaceutical company’s stock valued at $5,936,000 after purchasing an additional 74,608 shares during the last quarter. Geode Capital Management LLC increased its stake in Ultragenyx Pharmaceutical by 12.5% in the fourth quarter. Geode Capital Management LLC now owns 568,230 shares of the biopharmaceutical company’s stock valued at $24,706,000 after purchasing an additional 63,118 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Ultragenyx Pharmaceutical by 8.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,113 shares of the biopharmaceutical company’s stock valued at $216,000 after purchasing an additional 242 shares during the last quarter. Janney Montgomery Scott LLC purchased a new position in Ultragenyx Pharmaceutical in the first quarter valued at approximately $277,000. Finally, Rhumbline Advisers increased its stake in Ultragenyx Pharmaceutical by 14.1% in the first quarter. Rhumbline Advisers now owns 74,817 shares of the biopharmaceutical company’s stock valued at $5,189,000 after purchasing an additional 9,256 shares during the last quarter.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.

See Also: What is the NASDAQ Stock Market?

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.